| Schedule Of Expense Segment Reporting In formation |
The significant expense categories within net loss are presented on the condensed consolidated statements of operations. The research and development expenses have been disaggregated as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Tarcocimab program expenses |
|
$ |
11,886 |
|
|
$ |
9,157 |
|
|
$ |
26,162 |
|
|
$ |
15,126 |
|
KSI-501 and KSI-101 program expenses |
|
|
5,309 |
|
|
|
1,080 |
|
|
|
9,526 |
|
|
|
3,301 |
|
ABC Platform and other program expenses |
|
|
6,421 |
|
|
|
3,115 |
|
|
|
12,066 |
|
|
|
5,701 |
|
Payroll and personnel expenses |
|
|
14,109 |
|
|
|
14,492 |
|
|
|
28,379 |
|
|
|
28,851 |
|
Facilities and other research and development expenses |
|
|
5,035 |
|
|
|
4,670 |
|
|
|
10,271 |
|
|
|
9,466 |
|
Total research and development expenses |
|
$ |
42,760 |
|
|
$ |
32,514 |
|
|
$ |
86,404 |
|
|
$ |
62,445 |
|
|